BioSpace News Archive

Business

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced its financial results for the first quarter of 2024 and provided a corporate update.

May 7, 2024
·
8 min read
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference

Kiniksa Pharmaceuticals, Ltd. announced that management will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Tuesday, May 14, 2024 at 10:40 a.m. Pacific Time.

May 7, 2024
·
1 min read
Business

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced that the Company will report first quarter 2024 financial results on Tuesday, May 14, 2024.

May 7, 2024
·
1 min read
Business

Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, reported financial results for the first quarter ended March 31, 2024.

May 7, 2024
·
15 min read
Business

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Denali Therapeutics Inc. reported financial results for the first quarter ended March 31, 2024, and provided business highlights.

May 7, 2024
·
13 min read
Business

ClearPoint Neuro Reports First Quarter 2024 Results

ClearPoint Neuro, Inc., a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, announced financial results for its first quarter ended March 31, 2024.

May 7, 2024
·
12 min read
Business

Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced financial results for its first quarter ended March 31, 2024 and reiterated its previously issued outlook on business performance for the full-year 2024.

May 7, 2024
·
23 min read
Business

SIGA Reports Financial Results for Three Months Ended March 31, 2024

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, reported financial results for the three months ended March 31, 2024.

May 7, 2024
·
11 min read
Business

scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024

scPharmaceuticals Inc. announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, May 14th, 2024, to discuss the financial results for the first quarter 2024 and provide a business update.

May 7, 2024
·
1 min read
Business

Inspire Medical Systems, Inc. Announces First Quarter 2024 Financial Results and Updates 2024 Outlook

Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended March 31, 2024.

May 7, 2024
·
10 min read